GLP-1s are linked to an increase in heart rate and number of ventricular events in patients with heart failure with reduced ejection fraction and implanted cardiac devices.

Researchers are developing non-invasive saliva tests to detect heart failure early, potentially before symptoms appear.

Heart failure is a complex clinical syndrome affecting around 70 million individuals globally. It has a prevalence of 2% in ...

Acoramidis significantly reduced all-cause mortality in both wild-type and variant amyloid cardiomyopathy through 42 months of the ATTRibute-CM study. The study demonstrated consistent efficacy in ...

The Cardiac Biomarkers Market offers opportunities in developing high-sensitivity assays, point-of-care solutions for decentralized care, and AI-supported diagnostics. Growth is driven by rising ...

The ATTRibute-CM study's open-label extension showed that acoramidis effectively lowers all-cause mortality in patients with ...

The recent earnings call from BioCardia painted a picture of optimism tempered by financial challenges. The company showcased significant advancements in clinical trials and regulatory achievements, ...

Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for approximately 30% of global mortality ...

The FDA has granted Fast Track designation to VS-041, an investigational therapy for the treatment of heart failure with preserved ejection fraction.

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

As Hungary’s healthcare system continues its journey of integration and modernization, the role of high-quality, timely ...

ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure ...